Microart, Inc. Announces Stem Cell Agency Agreement
January 07 2014 - 5:25AM
Microart, Inc. ("MCRT" or the "Company") (OTC:MCRT), a Nevada
Corporation, is pleased to announce that it has signed an agency
agreement to market stem cell treatments in Germany to its clients
in Asia.
The Company has signed an agency agreement with Gali Klinik
Limited "Gali", based in Neustadt an der Weinstrabe, Germany.
Tsap Wai Ping, CEO stated, "our agreement with Gali is a
significant step forward in our business plan and developing our
stem cell therapy business with a global leader in the field."
Gali Klinik is a fully licensed Hospital in Germany, fully
compliant with government regulations to provide professional Fresh
Cell Therapy to patients. Gali Klinik, is committed to promoting
life-long physical well-being and youthful exuberance to its
patients. Gali believes that youth is not about a person's
appearance or the actual age. It is associated with one's
energy level, vitality, and physical wellbeing. This can be
achieved through the provision of the safest treatment with the
highest medical standards accompanied by our excellent services,
which are tailor-made for each patient.
Website: http://galiklinik.com/index.html
Microart Inc. is a global leader of innovative stem cell
solutions, the therapeutic applications of Adult stem cells and the
development and commercialization of cell-based anti-aging research
and cosmetic products. Microart Inc. is also developing proprietary
technology seeking to revolutionize the treatment of diabetes.
CONTACT: Tsap Wai Ping, President & CEO
Microart, Inc.
2611 Office Tower, Langham Place, 8 Argyle Street, Kowloon,
Hong Kong.
Tel +852-3111-7718
info@mcrtus.com
www.mcrtus.com
Microart (CE) (USOTC:MCRT)
Historical Stock Chart
From Nov 2024 to Dec 2024
Microart (CE) (USOTC:MCRT)
Historical Stock Chart
From Dec 2023 to Dec 2024